Paper831074
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
Toyka KV and 6 others. N Engl J Med, 1977. Cited by 379 papers, by iCite.
Cite this record
ConductScience Library. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. Papers, record 831074. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/831074
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunity | Major topic |
| Immunization, Passive | Major topic |
| Myasthenia Gravis | Major topic |
| Acetylcholine | |
| Adolescent | |
| Adult | |
| Aged | |
| Animals | |
| Autoimmune Diseases | |
| Complement C3 | |
| Complement C5 | |
| Female | |
| Humans | |
| Immunoglobulin G | |
| Immunoglobulin M | |
| Male | |
| Membrane Potentials | |
| Mice | |
| Middle Aged | |
| Neuromuscular Junction | |
| Receptors, Cholinergic |
Source PubMed
Cited by89
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 379 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42920067 | Current and Emerging Therapies for Generalized Myasthenia Gravis: Toward Precision Medicine. | Neurol Ther | 2026 | https://conductscience.org/library/papers/42920067 | PubMed |
| 42321519 | Narcolepsy is (not) an autoimmune disease. | Nat Rev Neurol | 2026 | https://conductscience.org/library/papers/42321519 | PubMed |
| 41118207 | Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/41118207 | PubMed |
| 41006369 | Refinement of the rat acetylcholine receptor-specific passive transfer myasthenia gravis model using subcutaneous injections: an update to the guidelines. | Sci Rep | 2025 | https://conductscience.org/library/papers/41006369 | PubMed |
| 40612406 | Fibromyalgia syndrome-am I an autoimmune condition? | Pain Rep | 2025 | https://conductscience.org/library/papers/40612406 | PubMed |
| 40257679 | Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation. | Neurol Ther | 2025 | https://conductscience.org/library/papers/40257679 | PubMed |
| 39111891 | Efgartigimod Successfully Ameliorated Acute Exacerbation of Myasthenia Gravis with Anti-muscle-specific Kinase Antibodies. | Intern Med | 2025 | https://conductscience.org/library/papers/39111891 | PubMed |
| 37559106 | Milestones in the history of neurocritical care. | Neurol Res Pract | 2023 | https://conductscience.org/library/papers/37559106 | PubMed |
| 36362622 | New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies. | J Clin Med | 2022 | https://conductscience.org/library/papers/36362622 | PubMed |
| 36074148 | Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities. | Acta Neuropathol | 2022 | https://conductscience.org/library/papers/36074148 | PubMed |
| 34426685 | Getting specific: targeting Fc receptors in myasthenia gravis. | Nat Rev Neurol | 2021 | https://conductscience.org/library/papers/34426685 | PubMed |
| 34196305 | Passive transfer of fibromyalgia symptoms from patients to mice. | J Clin Invest | 2021 | https://conductscience.org/library/papers/34196305 | PubMed |
| 32582144 | Complement Inhibitor Therapy for Myasthenia Gravis. | Front Immunol | 2020 | https://conductscience.org/library/papers/32582144 | PubMed |
| 32116982 | In vivo Mechanisms of Antibody-Mediated Neurological Disorders: Animal Models and Potential Implications. | Front Neurol | 2019 | https://conductscience.org/library/papers/32116982 | PubMed |
| 31482201 | Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. | J Neurol | 2021 | https://conductscience.org/library/papers/31482201 | PubMed |
| 30953561 | Anti-CNTN1 IgG3 induces acute conduction block and motor deficits in a passive transfer rat model. | J Neuroinflammation | 2019 | https://conductscience.org/library/papers/30953561 | PubMed |
| 29089519 | Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient. | Sci Rep | 2017 | https://conductscience.org/library/papers/29089519 | PubMed |
| 28620373 | Mechanisms of Autoantibody-Induced Pathology. | Front Immunol | 2017 | https://conductscience.org/library/papers/28620373 | PubMed |
| 26977423 | Immunoadsorption therapy in autoimmune encephalitides. | Neurol Neuroimmunol Neuroinflamm | 2016 | https://conductscience.org/library/papers/26977423 | PubMed |
| 26886206 | Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. | J Neurol | 2016 | https://conductscience.org/library/papers/26886206 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 | NCBI Gene |
| C5 | 727 | PubTator's text mining | https://conductscience.org/library/genes/727 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/831074
GET https://conductscience.org/api/papers/v1/831074/cited_by?page=2